Cargando…

Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia

Measurable (minimal) residual disease (MRD) status in acute lymphoblastic leukemia (ALL) has largely superseded the importance of traditional risk factors for ALL, such as baseline white blood cell count, cytogenetics, and immunophenotype, and has emerged as the most powerful independent prognostic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hein, Kyaw, Short, Nicholas, Jabbour, Elias, Yilmaz, Musa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943430/ https://www.ncbi.nlm.nih.gov/pubmed/35340663 http://dx.doi.org/10.2147/BLCTT.S270134

Ejemplares similares

Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
por: Abou Dalle, Iman, et al.
Publicado: (2020)

Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
por: Samra, Bachar, et al.
Publicado: (2020)

Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia
por: Guerra, Veronica A., et al.
Publicado: (2019)

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
por: Jabbour, Elias, et al.
Publicado: (2023)

Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients
por: Saygin, Caner, et al.
Publicado: (2022)

How I Use Measurable Residual Disease in the Clinical Management of Adult Acute Lymphoblastic Leukemia
por: Fernando, Fiona, et al.
Publicado: (2021)

Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
por: Savoy, J. Michael, et al.
Publicado: (2018)

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia
por: Kruse, Aaron, et al.
Publicado: (2020)

How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?
por: Short, Nicholas J., et al.
Publicado: (2019)

Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia
por: Aitken, Marisa J. L., et al.
Publicado: (2021)

Measurable residual disease in childhood B-cell acute lymphoblastic leukemia
por: Gale, Robert Peter
Publicado: (2022)

Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
por: Gibson, Amber, et al.
Publicado: (2021)

Minimal residual disease in acute lymphoblastic leukemia: technical aspects and implications for clinical interpretation
por: Kim, In-Suk
Publicado: (2020)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Sources of error in measurement of minimal residual disease in childhood acute lymphoblastic leukemia
por: Latham, Sue, et al.
Publicado: (2017)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Current Practice and Future Directions
por: Contreras Yametti, Gloria Paz, et al.
Publicado: (2021)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia
por: Rocha, Juliana Maria Camargos, et al.
Publicado: (2016)

Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
por: Kantarjian, Hagop, et al.
Publicado: (2023)

Minimal Residual Disease in Adult Acute Lymphoblastic Leukemia: Egyptian Experience
por: Ibrahim, Rasha Ibrahim, et al.
Publicado: (2022)

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY
por: Short, Nicholas, et al.
Publicado: (2023)

Blinatumomab for the Treatment of Adult B-Cell Acute Lymphoblastic Leukemia: Toward a New Era of Targeted Immunotherapy
por: Franquiz, Miguel J, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead
por: Pasvolsky, Oren, et al.
Publicado: (2023)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

Technical Advances in the Measurement of Residual Disease in Acute Myeloid Leukemia
por: Roloff, Gregory W., et al.
Publicado: (2017)

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2022)

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
por: Ching, Travers, et al.
Publicado: (2020)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

P364: A PHASE II STUDY OF LOW-INTENSITY CHEMOTHERAPY (MINI-HYPER-CVD) AND PONATINIB FOLLOWED BY BLINATUMOMAB AND PONATINIB IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
por: Haddad, Fadi, et al.
Publicado: (2023)

Clinical Challenges and Consequences of Measurable Residual Disease in Non-APL Acute Myeloid Leukemia
por: Jentzsch, Madlen, et al.
Publicado: (2019)

Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden
por: DeAngelo, Daniel J., et al.
Publicado: (2020)

The evolution of clinical trials for infant acute lymphoblastic leukemia
por: Kotecha, R S, et al.
Publicado: (2014)

T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness
por: Bardelli, Valentina, et al.
Publicado: (2021)

Mitochondrial DNA in Residual Leukemia Cells in Cerebrospinal Fluid in Children with Acute Lymphoblastic Leukemia
por: Egan, Kathryn, et al.
Publicado: (2010)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Circulating microRNAs as minimal residual disease biomarkers in childhood acute lymphoblastic leukemia
por: Rzepiel, Andrea, et al.
Publicado: (2019)

Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia
por: Azenkot, Tali, et al.
Publicado: (2022)

Prognostic Significance and Treatment Implications of Minimal Residual Disease Studies in Philadelphia-Negative Adult Acute Lymphoblastic Leukemia
por: Spinelli, Orietta, et al.
Publicado: (2014)

Insights into the prenatal origin of childhood acute lymphoblastic leukemia
por: Hein, Daniel, et al.
Publicado: (2020)

Treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens
por: Haddad, Fadi G., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vt1cbig2a22t2t1811alss72l4